Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).Toni K. Choueiri, Robert J. Motzer, Bernard Escudier et al.|Journal of Clinical Oncology|2016Cited by 2